Treatment of metastatic colorectal cancer: focus on panitumumab

Treatment of metastatic colorectal cancer: focus on panitumumab

Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combi...

Full description

Bibliographic Details
Main Authors:	Tay, Rebecca Y, Wong, Rachel, Hawkes, Eliza A
Format:	Online
Language:	English
Published:	Dove Medical Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484697/

Similar Items

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: López-Gómez, Miriam, et al.
Published: (2012)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
by: Peeters, Marc, et al.
Published: (2015)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
by: Kim, George P, et al.
Published: (2008)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
by: Bennett, L, et al.
Published: (2011)

The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials
by: Liang, Ruo-feng, et al.
Published: (2015)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
by: Yazdi, Mohammad Hossein, et al.
Published: (2015)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel, Shiven B, et al.
Published: (2015)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
by: Krawczyk, Paweł Adam, et al.
Published: (2013)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
by: Jingquan Jia, et al.
Published: (2018-08-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Kasagi, Yuta, et al.
Published: (2013)

Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution
by: SONODA, HIROMICHI, et al.
Published: (2013)

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
by: Karthaus, Meinolf, et al.
Published: (2016)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
by: Capalbo, Carlo, et al.
Published: (2014)

Panitumumab-Induced Acneiform Rash in a Patient with Metastatic Colon Adenocarcinoma
by: Martins-Filho, Paulo Ricardo Saquete, et al.
Published: (2013)

Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience
by: Daoud, Mohamed A., et al.
Published: (2016)

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
by: Koukakis, Reija, et al.
Published: (2016)

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review
by: Trojan, Jörg, et al.
Published: (2015)

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
by: Bendell, Johanna C., et al.
Published: (2016)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
by: Hezel, A F, et al.
Published: (2014)

Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer
by: Ko, S., et al.
Published: (2014)

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
by: Siena, Salvatore, et al.
Published: (2016)

Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study
by: Lakomy, Radek, et al.
Published: (2015)

Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients†
by: Boku, Narikazu, et al.
Published: (2014)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
by: Shitara, Kohei, et al.
Published: (2016)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer12
by: Gasparini, Giampietro, et al.
Published: (2014)

Aflibercept in the Treatment of Metastatic Colorectal Cancer
by: Wang, Tzu-Fei, et al.
Published: (2012)

Use of panitumumab in the treatment of acinar cell carcinoma of the pancreas: A case report
by: MORALES, MANUEL, et al.
Published: (2013)

Immunogenicity of panitumumab in combination chemotherapy clinical trials
by: Weeraratne, Dohan, et al.
Published: (2011)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
by: Burris, Howard, et al.
Published: (2011)

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
by: Liu, Yuguo, et al.
Published: (2015)

An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer
by: Poulin-Costello, Melanie, et al.
Published: (2013)

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
by: Thaler, Josef, et al.
Published: (2012)

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis
by: Zhou, Si-wei, et al.
Published: (2012)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
by: Di Bartolomeo, Maria, et al.
Published: (2015)

Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies
by: Popa, C, et al.
Published: (2012)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
by: Zoratto, Federica, et al.
Published: (2012)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
by: Yan, Yiyi, et al.
Published: (2015)

A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
by: Kim, Tae Won, et al.
Published: (2016)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
by: Bencsikova, Beatrix, et al.
Published: (2015)